MeSH term
Frequency | Condition_Probility | Albumins/metabolism | 3 | 2.0 |
Humans | 1546 | 0.0 |
Carcinoma, Hepatocellular/*drug therapy | 14 | 93.0 |
Cisplatin/administration & dosage | 47 | 23.0 |
Drug Administration Schedule | 23 | 2.0 |
Female | 947 | 1.0 |
Fluorouracil/administration & dosage | 12 | 9.0 |
Hepatic Artery | 25 | 48.0 |
*Infusion Pumps, Implantable | 3 | 42.0 |
Infusions, Intra-Arterial | 18 | 29.0 |
Liver Neoplasms/*drug therapy | 13 | 76.0 |
Male | 714 | 0.0 |
Middle Aged | 469 | 0.0 |
Neoplasm Circulating Cells/*pathology | 2 | 20.0 |
Portal Vein/*pathology | 2 | 25.0 |
Magnetic Resonance Imaging | 6 | 0.0 |
alpha-Fetoproteins/*analysis/cerebrospinal fluid | 2 | 100.0 |
Adult | 546 | 0.0 |
Aged | 321 | 1.0 |
Carcinoma, Hepatocellular/*drug therapy/mortality/*radiotherapy | 2 | 100.0 |
Iodine Radioisotopes/*therapeutic use | 2 | 6.0 |
Liver Neoplasms/*drug therapy/mortality/*radiotherapy | 2 | 100.0 |
Quality of Life | 2 | 1.0 |
Severity of Illness Index | 9 | 0.0 |
Survival Rate | 43 | 2.0 |
Treatment Outcome | 45 | 1.0 |
Animals | 190 | 0.0 |
Adolescent | 178 | 1.0 |
Aged, 80 and over | 62 | 0.0 |
*Biological Markers | 36 | 33.0 |
CA-19-9 Antigen/blood | 9 | 39.0 |
Carcinoembryonic Antigen/blood | 18 | 31.0 |
Carcinoma, Hepatocellular/*diagnosis | 21 | 91.0 |
Protein Precursors/blood | 2 | 5.0 |
Prothrombin | 7 | 14.0 |
ROC Curve | 20 | 10.0 |
Research Support, Non-U.S. Gov't | 404 | 0.0 |
Retrospective Studies | 77 | 2.0 |
Sensitivity and Specificity | 93 | 2.0 |
Tumor Markers, Biological/*blood | 85 | 17.0 |
alpha-Fetoproteins/analysis | 224 | 80.0 |
Immunohistochemistry | 75 | 0.0 |
Mutation | 5 | 0.0 |
Prognosis | 151 | 2.0 |
Protein p53/*metabolism | 2 | 0.0 |
Tumor Markers, Biological/metabolism | 5 | 1.0 |
*Catheter Ablation | 3 | 6.0 |
Combined Modality Therapy | 64 | 5.0 |
English Abstract | 315 | 2.0 |
Tegafur/administration & dosage | 9 | 50.0 |
Uracil/administration & dosage | 8 | 66.0 |
Biological Markers/analysis | 6 | 0.0 |
Chorionic Gonadotropin/blood | 41 | 42.0 |
Chorionic Gonadotropin, beta Subunit, Human/blood | 8 | 50.0 |
Estriol/blood | 12 | 36.0 |
Gestational Age | 77 | 8.0 |
Mass Screening/*methods | 6 | 11.0 |
Pregnancy/*blood | 26 | 16.0 |
Pregnancy Trimester, First | 36 | 13.0 |
Pregnancy Trimester, Second | 80 | 35.0 |
Prenatal Diagnosis/*methods | 33 | 26.0 |
Biological Markers/blood | 35 | 2.0 |
Protein Precursors/*blood | 4 | 5.0 |
alpha-Fetoproteins/biosynthesis | 5 | 41.0 |
Gene Expression Regulation, Neoplastic | 9 | 0.0 |
Liver Neoplasms/genetics/*pathology | 2 | 20.0 |
Reverse Transcriptase Polymerase Chain Reaction | 12 | 0.0 |
Carcinoma, Hepatocellular/genetics/*therapy | 3 | 100.0 |
Cell Line, Tumor | 6 | 0.0 |
Enhancer Elements (Genetics)/genetics | 3 | 4.0 |
Genetic Vectors/genetics | 2 | 0.0 |
Mice | 107 | 0.0 |
Mice, Nude | 37 | 1.0 |
Mutation/genetics | 2 | 0.0 |
Neoplasm Transplantation | 36 | 3.0 |
Promoter Regions (Genetics)/genetics | 4 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 13 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 109 | 0.0 |
Transfection | 14 | 0.0 |
alpha-Fetoproteins/*genetics | 47 | 88.0 |
Biological Markers | 13 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
gamma-Glutamyltransferase/*genetics | 3 | 33.0 |
Apoptosis | 3 | 0.0 |
Carcinoembryonic Antigen/analysis | 35 | 31.0 |
In Situ Nick-End Labeling | 2 | 0.0 |
Ki-67 Antigen/analysis | 2 | 0.0 |
Lung Neoplasms/metabolism/*pathology | 2 | 5.0 |
alpha-Fetoproteins/*biosynthesis | 50 | 90.0 |
Age of Onset | 4 | 0.0 |
Germany/epidemiology | 2 | 1.0 |
Hepatitis C/*complications | 4 | 22.0 |
Liver Cirrhosis/*complications | 7 | 33.0 |
Risk Factors | 56 | 0.0 |
Sex Factors | 18 | 1.0 |
Tumor Markers, Biological/*analysis | 38 | 3.0 |
alpha-Fetoproteins/*analysis | 445 | 95.0 |
Carcinoma, Hepatocellular/pathology/*surgery | 2 | 66.0 |
Child | 90 | 0.0 |
Disease-Free Survival | 8 | 0.0 |
Liver Neoplasms/pathology/*surgery | 2 | 66.0 |
Neoplasm Staging | 62 | 2.0 |
Predictive Value of Tests | 54 | 2.0 |
Antimetabolites, Antineoplastic/*therapeutic use | 2 | 5.0 |
Drug Combinations | 4 | 0.0 |
Liver Neoplasms/secondary | 9 | 13.0 |
Oxonic Acid/*therapeutic use | 2 | 100.0 |
Pyridines/*therapeutic use | 2 | 13.0 |
Tegafur/*therapeutic use | 2 | 40.0 |
Fluorodeoxyglucose F18/*diagnostic use | 2 | 15.0 |
Pilot Projects | 8 | 1.0 |
Prospective Studies | 61 | 1.0 |
Radiopharmaceuticals/*diagnostic use | 2 | 4.0 |
Chorionic Gonadotropin/*blood | 63 | 63.0 |
Estriol/*blood | 21 | 58.0 |
Genetic Counseling | 3 | 1.0 |
Neural Tube Defects/*diagnosis | 26 | 68.0 |
Pregnancy | 344 | 5.0 |
Prenatal Diagnosis/economics/*methods | 3 | 100.0 |
alpha-Fetoproteins/*metabolism | 138 | 95.0 |
Carcinoma, Hepatocellular/*blood/pathology | 5 | 83.0 |
Lectins/diagnostic use | 5 | 33.0 |
Liver Diseases/blood | 13 | 46.0 |
Liver Neoplasms/*blood/pathology | 6 | 85.0 |
*Plant Lectins | 20 | 19.0 |
Disease Progression | 15 | 0.0 |
Mice, Transgenic | 8 | 0.0 |
Liver Neoplasms/*diagnosis | 22 | 91.0 |
Tumor Necrosis Factor-alpha/analysis | 2 | 0.0 |
gamma-Glutamyltransferase/analysis | 2 | 16.0 |
Cells, Cultured | 15 | 0.0 |
Neoplasm Metastasis | 17 | 1.0 |
alpha-Fetoproteins/genetics | 9 | 42.0 |
Albumins/analysis | 4 | 10.0 |
Cell Division | 16 | 0.0 |
Clone Cells | 2 | 0.0 |
Flow Cytometry | 10 | 0.0 |
Hepatitis B Surface Antigens/analysis | 19 | 35.0 |
Hepatitis B virus/isolation & purification | 2 | 33.0 |
Keratin/analysis | 9 | 3.0 |
Liver/*pathology | 5 | 9.0 |
Mice, Inbred BALB C | 19 | 0.0 |
Neoplasm Invasiveness | 14 | 1.0 |
Virus Integration | 2 | 3.0 |
Carcinoma, Hepatocellular/*blood/diagnosis | 7 | 87.0 |
Liver Cirrhosis/blood | 14 | 34.0 |
Liver Neoplasms/*blood/diagnosis | 6 | 85.0 |
Transforming Growth Factor beta/*blood | 2 | 7.0 |
alpha-Fetoproteins/metabolism | 63 | 67.0 |
Carcinoembryonic Antigen/immunology | 3 | 21.0 |
Case-Control Studies | 26 | 0.0 |
Cross Reactions | 13 | 1.0 |
Reference Values | 43 | 0.0 |
alpha-Fetoproteins/immunology | 9 | 81.0 |
Carcinoma, Hepatocellular/*blood/therapy | 4 | 100.0 |
Chemoembolization, Therapeutic | 4 | 44.0 |
Liver Neoplasms/*blood/therapy | 4 | 100.0 |
*Neoplasm Circulating Cells | 5 | 12.0 |
RNA, Messenger/*blood | 4 | 11.0 |
Reproducibility of Results | 18 | 1.0 |
Follow-Up Studies | 71 | 2.0 |
*Liver Transplantation | 9 | 6.0 |
Liver/pathology | 18 | 9.0 |
Amniocentesis | 36 | 39.0 |
Amniotic Fluid/metabolism | 8 | 24.0 |
Incidence | 8 | 0.0 |
*Karyotyping | 2 | 12.0 |
New Jersey/epidemiology | 2 | 33.0 |
Prenatal Diagnosis/*standards | 2 | 66.0 |
Liver Neoplasms/*drug therapy/*secondary | 4 | 36.0 |
Stomach Neoplasms/*drug therapy/metabolism/pathology | 2 | 40.0 |
Lectins/*metabolism | 7 | 11.0 |
Prothrombin/metabolism | 3 | 4.0 |
Radioimmunoassay | 89 | 4.0 |
Tumor Markers, Biological/blood/*metabolism | 2 | 25.0 |
Carcinoma, Hepatocellular/*metabolism | 7 | 6.0 |
*Gene Expression Regulation | 7 | 0.0 |
Gene Silencing | 2 | 0.0 |
Liver Neoplasms/*metabolism | 5 | 5.0 |
Transcription, Genetic | 13 | 0.0 |
Tumor Cells, Cultured | 50 | 0.0 |
Calorimetry, Differential Scanning | 2 | 6.0 |
Circular Dichroism | 3 | 0.0 |
Fetal Blood | 6 | 4.0 |
Fluorometry | 2 | 2.0 |
Protein Conformation | 13 | 0.0 |
Spectrometry, Fluorescence | 5 | 1.0 |
alpha-Fetoproteins/*chemistry | 5 | 71.0 |
Autopsy | 3 | 1.0 |
Carcinoma, Hepatocellular/complications | 2 | 40.0 |
Lectins/metabolism | 7 | 8.0 |
Liver Neoplasms/complications | 2 | 33.0 |
Protein Binding | 12 | 0.0 |
alpha-Fetoproteins/*analysis/metabolism | 5 | 100.0 |
alpha-L-Fucosidase/*blood | 2 | 66.0 |
Carcinoma, Hepatocellular/*drug therapy/mortality | 2 | 66.0 |
Cisplatin/*therapeutic use | 3 | 9.0 |
Drug Carriers | 8 | 6.0 |
Iodine Radioisotopes | 3 | 0.0 |
Iodized Oil/administration & dosage | 7 | 43.0 |
Liver Neoplasms/*drug therapy/mortality | 2 | 66.0 |
Mitomycin/therapeutic use | 3 | 27.0 |
Antineoplastic Agents/*administration & dosage | 9 | 15.0 |
Child, Preschool | 61 | 0.0 |
Infant | 76 | 1.0 |
Infant, Newborn | 94 | 2.0 |
Tumor Markers, Biological/blood | 25 | 16.0 |
Polymerase Chain Reaction | 9 | 0.0 |
Protein p53/metabolism | 2 | 0.0 |
Liver Neoplasms/*chemistry | 6 | 25.0 |
Neoplasm Proteins/*analysis | 6 | 1.0 |
alpha-Fetoproteins/*analysis/biosynthesis | 2 | 100.0 |
Neoplasm Recurrence, Local | 27 | 6.0 |
Protein Precursors/*metabolism | 5 | 6.0 |
Prothrombin/*metabolism | 6 | 18.0 |
Survival Analysis | 25 | 1.0 |
Biological Markers/*blood | 11 | 6.0 |
Serum Albumin/analysis | 4 | 2.0 |
alpha 1-Antitrypsin/analysis | 8 | 9.0 |
Stomach Neoplasms/metabolism/*pathology/surgery | 3 | 42.0 |
Carcinoma, Hepatocellular/diagnosis/*metabolism | 3 | 100.0 |
Liver Neoplasms/diagnosis/*metabolism | 2 | 100.0 |
Diagnosis, Differential | 59 | 2.0 |
Immunoenzyme Techniques | 82 | 2.0 |
In Situ Hybridization | 4 | 0.0 |
Tumor Markers, Biological/analysis | 15 | 2.0 |
Hepatitis B Surface Antigens | 2 | 40.0 |
*Kidney Transplantation | 2 | 0.0 |
Liver Neoplasms/*radiotherapy | 2 | 100.0 |
Microspheres | 6 | 3.0 |
Analysis of Variance | 8 | 0.0 |
Comparative Study | 167 | 0.0 |
Multivariate Analysis | 21 | 1.0 |
Probability | 5 | 0.0 |
Antineoplastic Agents/therapeutic use | 9 | 3.0 |
Blotting, Northern | 9 | 0.0 |
Karyotyping | 12 | 0.0 |
Lung Neoplasms/secondary | 5 | 6.0 |
Testicular Neoplasms/*metabolism/pathology | 5 | 29.0 |
Carcinoma, Hepatocellular/*drug therapy/metabolism | 3 | 75.0 |
Disease Models, Animal | 3 | 0.0 |
Liver Neoplasms/*drug therapy/metabolism | 2 | 66.0 |
Carcinoma, Hepatocellular/*metabolism/pathology | 6 | 9.0 |
Liver Neoplasms/*metabolism/pathology | 6 | 8.0 |
Tumor Markers, Biological/*metabolism | 7 | 1.0 |
CD8-Positive T-Lymphocytes/immunology | 2 | 0.0 |
Cytotoxicity, Immunologic | 2 | 0.0 |
Hepatectomy | 14 | 19.0 |
Mice, Inbred C57BL | 5 | 0.0 |
T-Lymphocytes/*immunology | 3 | 0.0 |
Chorionic Gonadotropin, beta Subunit, Human/*blood | 11 | 84.0 |
*Prenatal Diagnosis | 90 | 33.0 |
Down-Regulation | 2 | 0.0 |
Chorionic Gonadotropin/analysis | 11 | 34.0 |
Chromosome Aberrations/diagnosis | 2 | 22.0 |
Chromosome Disorders | 19 | 5.0 |
Pregnancy-Associated Plasma Protein-A/*analysis | 4 | 22.0 |
Prenatal Diagnosis | 37 | 20.0 |
*Fetal Blood | 2 | 4.0 |
alpha-Fetoproteins/analysis/*isolation & purification | 3 | 100.0 |
Amino Acid Sequence | 23 | 0.0 |
Base Sequence | 36 | 0.0 |
Binding Sites | 7 | 0.0 |
*DNA-Binding Proteins | 2 | 0.0 |
Dexamethasone/*pharmacology | 2 | 0.0 |
Molecular Sequence Data | 42 | 0.0 |
Promoter Regions (Genetics)/*drug effects | 2 | 4.0 |
Rats | 41 | 0.0 |
Retinoid X Receptors | 2 | 0.0 |
Sequence Alignment | 2 | 0.0 |
Species Specificity | 7 | 0.0 |
alpha-Fetoproteins/biosynthesis/*genetics | 6 | 85.0 |
Carcinoma, Hepatocellular/*therapy | 13 | 54.0 |
Ganciclovir/pharmacology | 2 | 6.0 |
Gene Therapy/*methods | 4 | 0.0 |
*Genetic Vectors | 5 | 1.0 |
Liver Neoplasms/*therapy | 11 | 47.0 |
Thymidine Kinase/genetics | 2 | 2.0 |
*Transcription, Genetic | 2 | 0.0 |
Orchiectomy | 12 | 11.0 |
Neoplasm Proteins/analysis | 2 | 0.0 |
Cell Transformation, Neoplastic | 2 | 0.0 |
DNA, Neoplasm/genetics | 3 | 0.0 |
*Gene Expression Regulation, Neoplastic | 6 | 0.0 |
Hepatitis B, Chronic/*complications | 4 | 57.0 |
RNA, Messenger/biosynthesis | 4 | 0.0 |
RNA, Neoplasm/biosynthesis | 3 | 2.0 |
Sequence Analysis, DNA | 3 | 0.0 |
Inhibins/blood | 3 | 33.0 |
Carcinoma, Hepatocellular/blood/*drug therapy/pathology | 4 | 100.0 |
Liver Neoplasms/blood/*drug therapy/pathology | 5 | 100.0 |
Cell Differentiation | 7 | 0.0 |
Chromatography, Affinity | 27 | 3.0 |
Liver Cirrhosis/metabolism | 5 | 22.0 |
Radiotherapy, Adjuvant | 3 | 3.0 |
Platelet Count | 2 | 0.0 |
Recurrence | 11 | 0.0 |
Transaminases/blood | 3 | 16.0 |
Embryonic and Fetal Development/*physiology | 3 | 6.0 |
RNA, Messenger/*analysis | 3 | 0.0 |
*Embolization, Therapeutic | 8 | 34.0 |
Insulin-Like Growth Factor II/*analysis | 2 | 18.0 |
*Neoplasm Metastasis | 2 | 2.0 |
Chromatography, Affinity/methods | 2 | 2.0 |
Antibodies, Monoclonal/*immunology | 14 | 1.0 |
Enzyme-Linked Immunosorbent Assay | 21 | 0.0 |
alpha-Fetoproteins/chemistry/*immunology | 2 | 100.0 |
Hepatitis B, Chronic/*drug therapy | 2 | 33.0 |
Hepatitis C, Chronic/*drug therapy | 2 | 66.0 |
Time Factors | 63 | 0.0 |
Antigens, Tumor-Associated, Carbohydrate/blood | 7 | 46.0 |
CA-125 Antigen/blood | 9 | 31.0 |
CA-15-3 Antigen/blood | 2 | 15.0 |
Acute Disease | 6 | 0.0 |
Immunotherapy | 2 | 0.0 |
Lymphocyte Activation | 2 | 0.0 |
Models, Molecular | 3 | 0.0 |
alpha-Fetoproteins/*immunology | 25 | 89.0 |
Antibodies | 2 | 0.0 |
Binding, Competitive | 10 | 0.0 |
Dose-Response Relationship, Immunologic | 2 | 0.0 |
alpha-Fetoproteins/*analysis/immunology | 8 | 100.0 |
Antigenic Variation | 2 | 6.0 |
Epitope Mapping | 3 | 1.0 |
Gene Expression Regulation | 5 | 0.0 |
Hydrogen-Ion Concentration | 5 | 0.0 |
Immune Tolerance | 2 | 0.0 |
Maternal-Fetal Exchange | 12 | 9.0 |
Multigene Family | 2 | 0.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
Antibiotics, Antineoplastic/*administration & dosage | 5 | 38.0 |
Doxorubicin/*administration & dosage | 5 | 27.0 |
Gastrectomy | 6 | 10.0 |
Carcinoma, Hepatocellular/*etiology | 2 | 22.0 |
Hepatocytes/*pathology | 3 | 30.0 |
Liver Neoplasms/*etiology | 2 | 16.0 |
S Phase | 2 | 0.0 |
Carcinoma, Hepatocellular/blood/*metabolism | 2 | 100.0 |
Liver Neoplasms/blood/*metabolism | 2 | 100.0 |
Preoperative Care | 3 | 1.0 |
Carcinoma, Hepatocellular/pathology | 4 | 8.0 |
Gene Therapy | 3 | 0.0 |
*Genes, Regulator | 2 | 1.0 |
Genetic Engineering | 2 | 2.0 |
Liver Neoplasms/pathology | 3 | 6.0 |
Plasmids | 8 | 0.0 |
Tumor Cells, Cultured/metabolism | 2 | 1.0 |
Liver Neoplasms/*blood/*surgery | 2 | 66.0 |
Postoperative Period | 9 | 2.0 |
Hepatitis C, Chronic/*complications | 2 | 22.0 |
Longitudinal Studies | 5 | 0.0 |
United States | 3 | 0.0 |
Testicular Neoplasms/blood/*drug therapy/mortality | 2 | 100.0 |
Phenotype | 6 | 0.0 |
Promoter Regions (Genetics) | 17 | 0.0 |
Biopsy | 8 | 0.0 |
Carcinoma, Hepatocellular/*diagnosis/pathology/radiography | 2 | 100.0 |
Cholangiocarcinoma/*diagnosis/pathology/radiography | 2 | 100.0 |
Liver Regeneration | 6 | 12.0 |
Magnetic Resonance Imaging/*methods | 2 | 2.0 |
*Pregnancy Outcome | 3 | 5.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 36 | 7.0 |
Chemoembolization, Therapeutic/*methods | 3 | 75.0 |
Doxorubicin/administration & dosage | 21 | 11.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 38 | 7.0 |
Biopsy, Needle | 11 | 2.0 |
Carboplatin/administration & dosage | 3 | 7.0 |
Etoposide/administration & dosage | 20 | 17.0 |
Syndrome | 6 | 0.0 |
India | 3 | 0.0 |
Neural Tube Defects/*prevention & control | 3 | 75.0 |
Carcinoma, Hepatocellular/*enzymology | 4 | 16.0 |
Liver Neoplasms/*enzymology | 4 | 16.0 |
Fatal Outcome | 9 | 1.0 |
Carcinoma, Hepatocellular/*diagnosis/therapy | 4 | 100.0 |
Liver Neoplasms/*diagnosis/therapy | 4 | 100.0 |
Protein Isoforms/analysis | 2 | 4.0 |
Chorionic Gonadotropin, beta Subunit, Human/*analysis | 2 | 100.0 |
Endodermal Sinus Tumor/diagnosis | 2 | 100.0 |
Liver Neoplasms/diagnosis | 3 | 30.0 |
Neoplasms/*diagnosis | 5 | 33.0 |
Aneuploidy | 6 | 3.0 |
Down Syndrome/diagnosis | 8 | 61.0 |
Neural Tube Defects/diagnosis | 16 | 88.0 |
Oligohydramnios/blood | 3 | 100.0 |
Enhancer Elements (Genetics) | 8 | 2.0 |
Genetic Vectors | 6 | 0.0 |
Retroviridae/genetics | 5 | 1.0 |
Chronic Disease | 15 | 0.0 |
Logistic Models | 6 | 0.0 |
Odds Ratio | 4 | 0.0 |
Parity | 7 | 6.0 |
Regression Analysis | 14 | 0.0 |
Age Factors | 26 | 1.0 |
Area Under Curve | 2 | 0.0 |
Body Mass Index | 2 | 0.0 |
Cross-Sectional Studies | 3 | 0.0 |
Reference Standards | 3 | 1.0 |
Hepatitis B/*complications | 5 | 33.0 |
Proportional Hazards Models | 4 | 0.0 |
RNA, Messenger/metabolism | 5 | 0.0 |
Receptors, Cell Surface/*metabolism | 2 | 0.0 |
Bleomycin/administration & dosage | 31 | 43.0 |
Biological Assay | 3 | 1.0 |
Estradiol/*metabolism | 4 | 6.0 |
alpha-Fetoproteins/*pharmacology | 8 | 88.0 |
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage | 8 | 14.0 |
Cyclophosphamide/administration & dosage | 14 | 6.0 |
Doxorubicin/administration & dosage/analogs & derivatives | 3 | 37.0 |
Tomography, X-Ray Computed | 26 | 3.0 |
Apoptosis/drug effects | 2 | 0.0 |
Cell Division/drug effects | 8 | 0.0 |
Glycosylation | 4 | 0.0 |
alpha-Fetoproteins/*analysis/chemistry | 2 | 100.0 |
Cloning, Molecular | 17 | 0.0 |
*Genes, MHC Class I | 2 | 0.0 |
Testicular Neoplasms/*pathology | 5 | 35.0 |
Down Syndrome/*diagnosis/embryology | 2 | 100.0 |
European Continental Ancestry Group | 9 | 1.0 |
False Positive Reactions | 43 | 19.0 |
Fluorescent Antibody Technique | 11 | 0.0 |
Great Britain | 4 | 1.0 |
Pregnancy Trimester, Third | 7 | 3.0 |
Pregnancy, Multiple | 9 | 6.0 |
Cisplatin/*administration & dosage | 5 | 35.0 |
Hepatectomy/methods | 7 | 46.0 |
Infusions, Intravenous | 4 | 0.0 |
Liver Neoplasms/*drug therapy/pathology/surgery | 3 | 75.0 |
Albumins/genetics | 5 | 21.0 |
Carcinoma, Hepatocellular/*genetics/metabolism | 4 | 21.0 |
Gene Expression | 13 | 0.0 |
Gene Fusion | 2 | 2.0 |
Gene Targeting | 2 | 0.0 |
Liver Neoplasms/*genetics/metabolism | 4 | 15.0 |
Restriction Mapping | 5 | 0.0 |
alpha-Fetoproteins/*genetics/metabolism | 4 | 80.0 |
Blood Physiology | 2 | 2.0 |
Genetic Markers | 4 | 0.0 |
Hepatitis B, Chronic/complications | 2 | 66.0 |
Hepatitis C, Chronic/complications | 2 | 33.0 |
Liver Cirrhosis/complications | 12 | 37.0 |
Lymph Nodes/pathology | 2 | 0.0 |
Lymphatic Metastasis | 25 | 2.0 |
*Chromosomes, Human, Pair 18 | 6 | 4.0 |
*Trisomy | 12 | 10.0 |
*Aneuploidy | 5 | 5.0 |
Chromosomes, Human, Pair 13 | 3 | 2.0 |
Chromosomes, Human, Pair 18 | 6 | 5.0 |
Pregnancy-Associated Plasma Protein-A/analysis | 3 | 16.0 |
Trisomy | 4 | 3.0 |
Chromosome Mapping | 2 | 0.0 |
DNA Mutational Analysis | 4 | 0.0 |
Haplotypes | 2 | 0.0 |
Pedigree | 9 | 0.0 |
Carcinoma, Hepatocellular/blood | 12 | 75.0 |
Hepatitis/blood | 6 | 40.0 |
Carcinoma, Hepatocellular/complications/*diagnosis | 4 | 100.0 |
Liver Neoplasms/complications/*diagnosis | 3 | 100.0 |
Down Syndrome/*diagnosis | 25 | 78.0 |
Mass Screening | 13 | 7.0 |
Receptors, Estrogen/*metabolism | 3 | 1.0 |
Adenocarcinoma/*chemistry/pathology | 2 | 4.0 |
Antigens, Tumor-Associated, Carbohydrate/*analysis | 2 | 6.0 |
Carcinoma, Hepatocellular/*chemistry/pathology | 2 | 28.0 |
Liver Neoplasms/*chemistry/pathology | 2 | 28.0 |
Membrane Glycoproteins/analysis | 2 | 0.0 |
Ultrasonography | 25 | 31.0 |
Neoplasm Proteins/*metabolism | 2 | 0.0 |
Alanine Transaminase/blood | 13 | 6.0 |
Aminopeptidases/*blood | 2 | 40.0 |
Carcinoma, Hepatocellular/*diagnosis/enzymology | 2 | 100.0 |
Isoenzymes/*blood | 5 | 10.0 |
Liver Neoplasms/*diagnosis/enzymology | 2 | 100.0 |
Ferritin/blood | 4 | 2.0 |
RNA, Messenger/biosynthesis/genetics | 2 | 0.0 |
*Gestational Age | 8 | 13.0 |
Maternal Age | 32 | 34.0 |
Pregnancy, High-Risk | 14 | 33.0 |
Ultrasonography, Prenatal | 11 | 16.0 |
Antigens, CD95/*blood | 2 | 11.0 |
Carcinoma, Hepatocellular/blood/radiography/*therapy | 2 | 100.0 |
*Embolization, Therapeutic/methods | 4 | 50.0 |
Liver Neoplasms/blood/radiography/*therapy | 2 | 100.0 |
Necrosis | 11 | 3.0 |
*Pregnancy, High-Risk | 2 | 40.0 |
Carcinoma, Hepatocellular/*blood | 13 | 65.0 |
Liver Neoplasms/*blood | 15 | 62.0 |
Carcinoma, Hepatocellular | 5 | 1.0 |
DNA Replication | 2 | 0.0 |
Hela Cells | 8 | 0.0 |
Recombinant Fusion Proteins/genetics/metabolism | 2 | 0.0 |
Templates, Genetic | 3 | 1.0 |
Xenopus | 2 | 0.0 |
Fetal Diseases/diagnosis | 7 | 30.0 |
Solutions | 2 | 1.0 |
RNA, Messenger/analysis | 7 | 0.0 |
Tumor Markers, Biological/*genetics | 2 | 1.0 |
CA-125 Antigen/*blood | 4 | 36.0 |
CA-19-9 Antigen/*blood | 4 | 36.0 |
Carcinoembryonic Antigen/*blood | 7 | 30.0 |
Tissue Distribution | 11 | 0.0 |
Alkaline Phosphatase/analysis | 6 | 11.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Receptors, Estrogen/analysis | 3 | 0.0 |
Tumor Markers, Biological/biosynthesis | 3 | 7.0 |
Chorionic Gonadotropin, beta Subunit, Human/*urine | 2 | 100.0 |
*Infant, Small for Gestational Age | 2 | 11.0 |
Gastroscopy | 2 | 4.0 |
Phosphopyruvate Hydratase/analysis | 2 | 2.0 |
Vinblastine/administration & dosage | 22 | 53.0 |
Carcinoma, Hepatocellular/blood/*diagnosis | 7 | 100.0 |
Liver Cirrhosis/blood/diagnosis | 2 | 66.0 |
Liver Neoplasms/blood/*diagnosis | 9 | 100.0 |
*Gene Therapy | 5 | 1.0 |
Liver Neoplasms/pathology/*therapy | 2 | 28.0 |
Carcinoma, Hepatocellular/*pathology/surgery | 3 | 75.0 |
Antibodies, Monoclonal/*diagnostic use | 9 | 4.0 |
Neoplasm, Residual | 4 | 4.0 |
alpha-Fetoproteins/*immunology/metabolism | 4 | 100.0 |
alpha-Fetoproteins/analysis/*biosynthesis | 13 | 100.0 |
Administration, Oral | 6 | 0.0 |
Bone Neoplasms/*secondary | 3 | 30.0 |
Lung Neoplasms/*secondary | 2 | 16.0 |
Protein Precursors/metabolism | 2 | 1.0 |
Protein Precursors/*analysis | 7 | 28.0 |
Prothrombin/*analysis | 7 | 22.0 |
*Chemoembolization, Therapeutic | 10 | 40.0 |
Liver Neoplasms/surgery/*therapy | 2 | 66.0 |
Cohort Studies | 8 | 0.0 |
Down Syndrome/blood/*diagnosis | 10 | 76.0 |
False Negative Reactions | 15 | 10.0 |
L-Lactate Dehydrogenase/*blood | 3 | 10.0 |
Carcinoembryonic Antigen/metabolism | 3 | 15.0 |
Albumins/*genetics | 5 | 45.0 |
Evaluation Studies | 19 | 2.0 |
Protein Precursors/*blood/*metabolism | 2 | 100.0 |
*Tumor Markers, Biological | 6 | 3.0 |
Liver Neoplasms/*pathology | 11 | 19.0 |
RNA, Messenger/genetics | 3 | 0.0 |
Germinoma/*blood | 2 | 100.0 |
Immunoradiometric Assay/methods | 2 | 14.0 |
Radioimmunoassay/methods | 11 | 7.0 |
Testicular Neoplasms/*blood | 7 | 77.0 |
Antibodies, Monoclonal | 13 | 0.0 |
Chemiluminescent Measurements | 3 | 1.0 |
Amniocentesis/*adverse effects | 2 | 100.0 |
Fetomaternal Transfusion/*etiology | 4 | 100.0 |
Hepacivirus/immunology | 3 | 16.0 |
Hepatitis B virus/immunology | 4 | 22.0 |
Hepatitis C Antibodies/blood | 3 | 23.0 |
alpha-Fetoproteins/isolation & purification | 2 | 66.0 |
Carcinoma, Hepatocellular/blood/*diagnosis/pathology | 3 | 75.0 |
Liver Neoplasms/blood/*diagnosis/pathology | 3 | 75.0 |
*Reagent Kits, Diagnostic | 6 | 10.0 |
Age Distribution | 3 | 0.0 |
Sex Distribution | 3 | 1.0 |
Taiwan/epidemiology | 2 | 1.0 |
Concanavalin A | 9 | 18.0 |
Electrophoresis | 8 | 2.0 |
Fetal Blood/chemistry | 7 | 12.0 |
Fetus/*metabolism | 4 | 5.0 |
Immunoelectrophoresis, Two-Dimensional | 11 | 8.0 |
alpha-Fetoproteins/chemistry/*physiology | 3 | 100.0 |
Carbohydrate Conformation | 9 | 7.0 |
Carbohydrate Sequence | 9 | 2.0 |
Chromatography, High Pressure Liquid | 4 | 0.0 |
Liver Neoplasms/*secondary/*surgery | 2 | 40.0 |
Stomach Neoplasms/metabolism/*pathology | 6 | 18.0 |
Carcinoma, Hepatocellular/blood/diagnosis | 3 | 75.0 |
Cell Line | 23 | 0.0 |
Liver Neoplasms/blood/diagnosis | 4 | 66.0 |
Swine | 6 | 0.0 |
Antibodies, Monoclonal/chemistry/*genetics | 2 | 66.0 |
Immunoglobulin Variable Region/genetics | 2 | 1.0 |
Immunoglobulins, kappa-Chain/genetics | 2 | 6.0 |
Carcinoma, Hepatocellular/blood/*diagnosis/surgery | 2 | 100.0 |
Cesarean Section | 2 | 3.0 |
Focal Nodular Hyperplasia/blood/diagnosis | 2 | 100.0 |
Liver Neoplasms/blood/*diagnosis/surgery | 2 | 100.0 |
Neural Tube Defects/blood/diagnosis | 2 | 100.0 |
Pregnancy Complications, Neoplastic/blood/*diagnosis/surgery | 2 | 100.0 |
Acetaminophen/poisoning | 2 | 66.0 |
Bile Ducts, Intrahepatic/*chemistry/*cytology/drug effects/pathology | 2 | 100.0 |
Liver/*chemistry/*cytology/drug effects/pathology | 2 | 100.0 |
Portal System/cytology | 2 | 100.0 |
Proto-Oncogene Protein c-kit/analysis | 3 | 6.0 |
Stem Cells/*chemistry/*cytology/drug effects/pathology | 2 | 100.0 |
Contrast Media | 2 | 3.0 |
*Tomography, Emission-Computed | 2 | 4.0 |
Adenocarcinoma/*metabolism | 4 | 4.0 |
Keratin/*analysis | 4 | 13.0 |
*Chromosomes, Human, Pair 13 | 2 | 1.0 |
California/epidemiology | 2 | 5.0 |
*Continental Population Groups | 4 | 15.0 |
Genetic Screening | 5 | 0.0 |
Prevalence | 8 | 0.0 |
Normal Distribution | 3 | 15.0 |
Sex Characteristics | 4 | 0.0 |
In Vitro | 15 | 0.0 |
Liver/*metabolism | 4 | 0.0 |
Aging | 4 | 1.0 |
Cattle | 4 | 0.0 |
Serum Albumin/*analysis | 3 | 11.0 |
Protein Structure, Secondary | 3 | 0.0 |
Structure-Activity Relationship | 7 | 0.0 |
*Fertilization in Vitro | 4 | 3.0 |
Pregnancy Outcome | 12 | 4.0 |
Pregnancy, Multiple/blood | 2 | 66.0 |
Medical Records | 2 | 2.0 |
Teratoma/pathology/*surgery | 3 | 100.0 |
Testicular Neoplasms/pathology/*surgery | 4 | 100.0 |
Testis/pathology | 3 | 6.0 |
Amniotic Fluid/*chemistry/metabolism | 2 | 50.0 |
Electrophoresis/*methods | 2 | 8.0 |
Lectins | 11 | 11.0 |
Carcinoma, Hepatocellular/*blood/surgery | 4 | 100.0 |
Intercellular Adhesion Molecule-1/*blood | 2 | 3.0 |
Liver Neoplasms/*blood/surgery | 2 | 100.0 |
Neoplasm Recurrence, Local/blood | 2 | 12.0 |
Cross-Linking Reagents | 3 | 0.0 |
Dose-Response Relationship, Drug | 10 | 0.0 |
Solubility | 5 | 0.0 |
Teratoma/*metabolism | 2 | 40.0 |
Testicular Neoplasms/*metabolism | 4 | 36.0 |
Monitoring, Physiologic | 3 | 3.0 |
Mice, SCID | 4 | 0.0 |
Tumor Cells, Cultured/drug effects | 2 | 0.0 |
Liver/chemistry/pathology | 2 | 12.0 |
Liver Function Tests | 6 | 3.0 |
Liver Transplantation | 3 | 5.0 |
Alanine Transaminase/*blood | 2 | 8.0 |
Nuclear Proteins/metabolism | 4 | 0.0 |
Blood Proteins/*metabolism | 3 | 1.0 |
alpha 1-Antitrypsin/metabolism | 3 | 6.0 |
Hepatitis B/complications | 9 | 36.0 |
Hepatitis B Surface Antigens/blood | 7 | 26.0 |
Italy/epidemiology | 4 | 1.0 |
Liver Cirrhosis/*complications/pathology/ultrasonography | 2 | 100.0 |
Liver Cirrhosis, Alcoholic/complications | 3 | 33.0 |
*Sex Characteristics | 3 | 2.0 |
Cisplatin/therapeutic use | 8 | 20.0 |
Ovarian Neoplasms/*drug therapy/pathology | 2 | 8.0 |
Colorectal Neoplasms/*pathology | 2 | 3.0 |
Postoperative Complications | 3 | 2.0 |
Tumor Markers, Biological/*diagnostic use | 2 | 25.0 |
Enzyme Tests | 3 | 4.0 |
Pregnancy-Specific beta 1-Glycoproteins/analysis | 5 | 14.0 |
Uterine Neoplasms/*diagnosis | 2 | 50.0 |
Antibody Specificity | 14 | 1.0 |
Inhibins/*blood | 4 | 36.0 |
*Prenatal Diagnosis/methods | 2 | 100.0 |
Immunization | 2 | 0.0 |
Aspartate Aminotransferases/blood | 11 | 8.0 |
Emulsions | 3 | 4.0 |
Epirubicin/*administration & dosage/therapeutic use | 2 | 100.0 |
*Hepatic Artery | 2 | 66.0 |
L-Lactate Dehydrogenase/blood | 7 | 6.0 |
Water | 2 | 3.0 |
Gene Expression Regulation, Developmental | 3 | 0.0 |
Regulatory Sequences, Nucleic Acid | 3 | 0.0 |
alpha-Fetoproteins/*biosynthesis/genetics | 3 | 75.0 |
DNA Primers | 2 | 0.0 |
Endodermal Sinus Tumor/*pathology | 2 | 100.0 |
Peritoneal Neoplasms/*secondary | 2 | 25.0 |
*Pineal Gland | 3 | 42.0 |
Antigens, Neoplasm/*blood | 2 | 4.0 |
Asian Continental Ancestry Group | 4 | 1.0 |
Carcinoma, Hepatocellular/*diagnosis/pathology | 6 | 66.0 |
Immunoradiometric Assay | 5 | 4.0 |
Liver Neoplasms/*diagnosis/pathology | 6 | 60.0 |
Antineoplastic Agents/*therapeutic use | 8 | 2.0 |
Carcinoma, Hepatocellular/*drug therapy/pathology | 4 | 57.0 |
Iodized Oil/*administration & dosage | 9 | 75.0 |
Liver Neoplasms/*drug therapy/pathology | 8 | 72.0 |
Maleic Anhydrides/*administration & dosage | 3 | 100.0 |
Polystyrenes/*administration & dosage | 3 | 100.0 |
Zinostatin/administration & dosage/*analogs & derivatives | 3 | 100.0 |
Reoperation | 6 | 4.0 |
Carcinoma, Hepatocellular/*pathology | 9 | 18.0 |
Cell Division/*drug effects | 2 | 0.0 |
Embryo Transfer | 2 | 2.0 |
Twins | 8 | 20.0 |
Chorionic Gonadotropin/*metabolism | 4 | 26.0 |
Binding Sites/genetics | 2 | 0.0 |
Carcinoma, Hepatocellular/genetics/metabolism | 3 | 23.0 |
DNA Primers/genetics | 3 | 0.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
Liver Neoplasms/genetics/metabolism | 3 | 23.0 |
Nuclear Proteins/genetics | 2 | 0.0 |
*Transcription Factors | 2 | 0.0 |
Biological Transport | 4 | 0.0 |
Placenta/*metabolism | 2 | 1.0 |
Placental Lactogen/metabolism | 3 | 17.0 |
Antibiotics, Antineoplastic/administration & dosage | 4 | 25.0 |
Gelatin Sponge, Absorbable | 2 | 50.0 |
Iodized Oil/therapeutic use | 2 | 100.0 |
Animals, Newborn | 2 | 0.0 |
Hepatitis, Chronic/blood | 3 | 60.0 |
*Protein Precursors | 9 | 50.0 |
Prothrombin/*analogs & derivatives/analysis | 7 | 100.0 |
Transplantation, Heterologous | 14 | 1.0 |
alpha-Fetoproteins/isolation & purification/*pharmacology | 2 | 66.0 |
Chorionic Gonadotropin/*analysis | 19 | 54.0 |
Blotting, Western | 5 | 0.0 |
Chromatography, Ion Exchange | 5 | 1.0 |
Electrophoresis, Polyacrylamide Gel | 20 | 0.0 |
Fetal Blood/*chemistry | 6 | 10.0 |
Immunoelectrophoresis | 10 | 4.0 |
Isoenzymes/analysis | 4 | 7.0 |
Staining and Labeling | 7 | 1.0 |
Risk | 33 | 3.0 |
Adenocarcinoma/*metabolism/pathology | 5 | 4.0 |
Carcinoma, Endometrioid/*metabolism/pathology | 2 | 28.0 |
Ovarian Neoplasms/*metabolism/pathology | 5 | 7.0 |
Mitotic Index | 2 | 1.0 |
Testicular Neoplasms/*blood/pathology/therapy | 3 | 100.0 |
Liver Neoplasms/blood/*pathology/therapy | 3 | 100.0 |
RNA, Messenger/blood | 2 | 3.0 |
alpha-Fetoproteins/biosynthesis/genetics | 3 | 75.0 |
*Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Fetal Diseases/*diagnosis | 18 | 45.0 |
Liver Cirrhosis/diagnosis | 8 | 72.0 |
Tumor Markers, Biological | 7 | 1.0 |
Carrier Proteins/*blood | 2 | 0.0 |
Dihydrotestosterone/blood | 2 | 2.0 |
Estradiol/*blood | 5 | 3.0 |
Sex Hormone-Binding Globulin/metabolism | 3 | 1.0 |
Testosterone/blood | 2 | 0.0 |
Calibration | 2 | 1.0 |
Neoplasms/*blood/diagnosis | 2 | 8.0 |
Tumor Markers, Biological/*blood/immunology | 2 | 40.0 |
Concanavalin A/pharmacology | 4 | 1.0 |
Antibody Affinity | 4 | 2.0 |
*Antibody Affinity | 3 | 16.0 |
Epitopes | 6 | 0.0 |
Carcinoma, Renal Cell/*blood/pathology | 2 | 100.0 |
Kidney Neoplasms/*blood/pathology | 2 | 66.0 |
Precancerous Conditions/diagnosis | 2 | 50.0 |
Remission Induction | 18 | 3.0 |
Tegafur/*administration & dosage | 2 | 66.0 |
Endodermal Sinus Tumor/metabolism/pathology | 2 | 66.0 |
Japan | 3 | 0.0 |
Carcinoma, Hepatocellular/*chemistry | 5 | 22.0 |
*Bile Ducts, Intrahepatic | 2 | 6.0 |
Estriol/*urine | 3 | 100.0 |
Lymphocyte Activation/*drug effects | 6 | 1.0 |
Peptides/analysis | 2 | 2.0 |
Serum Albumin | 3 | 9.0 |
Vitamin D-Binding Protein/*genetics | 2 | 3.0 |
Antibodies, Monoclonal/analysis | 2 | 2.0 |
Carcinoma, Hepatocellular/*radionuclide imaging | 3 | 100.0 |
Iodine Radioisotopes/diagnostic use | 5 | 1.0 |
Liver Neoplasms/*radionuclide imaging | 3 | 100.0 |
alpha-Fetoproteins/analysis/*immunology | 7 | 100.0 |
Carcinoma, Hepatocellular/blood/*drug therapy | 2 | 50.0 |
Liver Neoplasms/blood/*drug therapy | 2 | 50.0 |
Mass Screening/methods | 4 | 8.0 |
Pregnancy Complications/*blood | 7 | 20.0 |
Neoplasms, Germ Cell and Embryonal/*metabolism | 2 | 33.0 |
Pregnancy/*metabolism | 5 | 8.0 |
Radioimmunoassay/*methods | 5 | 6.0 |
Electrophoresis, Agar Gel | 9 | 1.0 |
Immunoblotting | 2 | 0.0 |
Birth Weight | 12 | 7.0 |
Blood Pressure | 2 | 0.0 |
Fetal Growth Retardation/*blood | 2 | 13.0 |
Organ Size | 4 | 2.0 |
Neoplasm Proteins/blood | 2 | 12.0 |
Risk Assessment | 6 | 0.0 |
Statistics, Nonparametric | 3 | 0.0 |
alpha-Fetoproteins/analysis/*metabolism | 7 | 87.0 |
Liver Cirrhosis/*pathology | 2 | 25.0 |
Genomic Library | 2 | 0.0 |
H-2 Antigens/genetics | 3 | 12.0 |
Pregnancy Complications | 2 | 7.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 2 | 0.0 |
Liver Neoplasms | 11 | 3.0 |
Tretinoin/*pharmacology | 2 | 0.0 |
Adenoviridae/*genetics | 5 | 2.0 |
Antineoplastic Agents/*pharmacology | 2 | 0.0 |
Testicular Neoplasms/metabolism/*pathology | 3 | 50.0 |
Genetic Screening/*methods | 2 | 1.0 |
Half-Life | 12 | 2.0 |
Nephroblastoma/diagnosis | 2 | 100.0 |
Stomach Neoplasms/chemistry/*pathology | 2 | 18.0 |
Antibodies, Monoclonal/therapeutic use | 2 | 1.0 |
Carcinoma, Hepatocellular/mortality/*therapy | 2 | 66.0 |
Immunotoxins/*therapeutic use | 3 | 6.0 |
Liver Neoplasms/mortality/*therapy | 3 | 75.0 |
DNA, Neoplasm/*genetics | 3 | 1.0 |
Fetus | 6 | 1.0 |
Liver/metabolism | 8 | 0.0 |
Placenta/metabolism | 2 | 1.0 |
Pregnancy-Specific beta 1-Glycoproteins/*metabolism | 2 | 10.0 |
Ligands | 5 | 0.0 |
Protein Denaturation | 3 | 1.0 |
Serum Albumin/chemistry | 2 | 25.0 |
Carcinoma, Hepatocellular/metabolism/*pathology | 3 | 17.0 |
Protein Precursors/analysis | 5 | 11.0 |
CA-19-9 Antigen/analysis | 3 | 23.0 |
Colorectal Neoplasms/*chemistry | 2 | 16.0 |
Adenocarcinoma/metabolism/*secondary/surgery | 2 | 66.0 |
Alleles | 3 | 0.0 |
Enzyme-Linked Immunosorbent Assay/methods | 3 | 1.0 |
Neural Tube Defects/diagnosis/epidemiology | 2 | 100.0 |
Statistics | 6 | 1.0 |
Blotting, Southern | 5 | 0.0 |
Biological Response Modifiers/chemistry/*physiology | 2 | 100.0 |
Hepatoblastoma/*diagnosis | 2 | 100.0 |
Antigens, Neoplasm/analysis | 4 | 1.0 |
Antigens, Tumor-Associated, Carbohydrate/analysis | 3 | 15.0 |
*Serpins | 3 | 18.0 |
*Abortion, Induced | 5 | 22.0 |
Fetal Hemoglobin/*analysis | 2 | 12.0 |
Bleomycin/administration & dosage/adverse effects | 2 | 18.0 |
Cause of Death | 3 | 1.0 |
Chemotherapy, Adjuvant | 9 | 4.0 |
Cisplatin/administration & dosage/adverse effects | 3 | 12.0 |
*Transplantation, Heterologous | 2 | 2.0 |
Embolization, Therapeutic | 4 | 23.0 |
Transforming Growth Factor beta/*urine | 2 | 100.0 |
Feasibility Studies | 3 | 1.0 |
Liver Neoplasms/*blood/drug therapy/surgery | 2 | 100.0 |
Brain Neoplasms/drug therapy/radiotherapy/*therapy | 2 | 50.0 |
Neoplasms, Germ Cell and Embryonal/drug therapy/radiotherapy/*therapy | 2 | 100.0 |
Neoplasm Recurrence, Local/*blood | 2 | 33.0 |
RNA, Messenger/*analysis/blood | 2 | 100.0 |
*Ultrasonography, Prenatal | 3 | 9.0 |
Breast Neoplasms/diagnosis/*metabolism | 2 | 18.0 |
Carcinoma, Ductal, Breast/diagnosis/*metabolism | 2 | 33.0 |
Menopause | 2 | 0.0 |
Hepatitis B/blood | 4 | 50.0 |
Hepatitis, Chronic/*blood | 2 | 16.0 |
alpha-Fetoproteins/*analysis/genetics | 2 | 100.0 |
*Tomography, X-Ray Computed | 3 | 3.0 |
Amniotic Fluid/*chemistry | 9 | 19.0 |
Software | 3 | 1.0 |
Testicular Neoplasms/blood/*drug therapy/pathology | 2 | 100.0 |
Phosphopyruvate Hydratase/*blood | 2 | 11.0 |
Cell Survival/drug effects | 3 | 0.0 |
Prothrombin/analysis | 3 | 4.0 |
Down Syndrome/*blood | 3 | 27.0 |
Macromolecular Substances | 2 | 0.0 |
*Neoplasms, Multiple Primary | 3 | 25.0 |
Mediastinal Neoplasms/drug therapy/surgery/*therapy | 2 | 100.0 |
Prostate-Specific Antigen/blood | 3 | 3.0 |
*Genes, p53 | 2 | 0.0 |
Organ Specificity | 6 | 0.0 |
Infant, Premature | 6 | 5.0 |
Infant, Small for Gestational Age | 4 | 20.0 |
Neuraminidase/metabolism | 2 | 6.0 |
Phytohemagglutinins | 2 | 2.0 |
beta-Galactosidase/metabolism | 2 | 1.0 |
Doxorubicin/therapeutic use | 3 | 5.0 |
Fluorouracil/therapeutic use | 4 | 8.0 |
Mitomycin/administration & dosage | 4 | 10.0 |
Survivors | 2 | 2.0 |
Blood Chemical Analysis | 2 | 4.0 |
Maleic Anhydrides/administration & dosage | 2 | 100.0 |
Polystyrenes/administration & dosage | 2 | 100.0 |
Zinostatin/administration & dosage/analogs & derivatives | 2 | 100.0 |
Amniotic Fluid/chemistry | 5 | 14.0 |
beta-Galactosidase/genetics | 2 | 1.0 |
Body Weight | 4 | 0.0 |
Continental Population Groups | 4 | 2.0 |
Glycoprotein Hormones, alpha Subunit/blood | 3 | 60.0 |
*Maternal Age | 3 | 42.0 |
*Parity | 2 | 22.0 |
African Continental Ancestry Group | 6 | 2.0 |
Doxorubicin/administration & dosage/*analogs & derivatives | 2 | 28.0 |
Epirubicin/administration & dosage | 4 | 11.0 |
Alaska | 3 | 33.0 |
*Carrier State | 2 | 18.0 |
*Inuits | 2 | 20.0 |
*Mass Screening | 6 | 11.0 |
Carcinoma, Hepatocellular/diagnosis/epidemiology/*therapy | 2 | 100.0 |
Ethanol/*administration & dosage | 2 | 11.0 |
Injections, Intralesional | 2 | 4.0 |
Liver Cirrhosis/epidemiology | 2 | 50.0 |
Liver Neoplasms/diagnosis/epidemiology/*therapy | 2 | 100.0 |
Neoplasm Recurrence, Local/*epidemiology | 2 | 33.0 |
Abnormalities/epidemiology | 2 | 33.0 |
Leiomyoma/blood | 2 | 100.0 |
Receptor, erbB-2/*blood | 2 | 28.0 |
Uterine Neoplasms/blood | 2 | 28.0 |
Carcinoma, Hepatocellular/metabolism | 4 | 4.0 |
Kidney/metabolism | 2 | 0.0 |
Liver Neoplasms/metabolism | 5 | 7.0 |
Molecular Weight | 13 | 0.0 |
Thermodynamics | 2 | 0.0 |
Adenocarcinoma/*blood | 2 | 14.0 |
Program Evaluation | 2 | 4.0 |
Taiwan | 3 | 1.0 |
Antigens, Neoplasm/blood | 2 | 9.0 |
Peptides/blood | 3 | 8.0 |
Tissue Polypeptide Antigen | 8 | 29.0 |
Prenatal Diagnosis/methods | 5 | 17.0 |
Reagent Kits, Diagnostic | 5 | 3.0 |
Down Syndrome/*diagnosis/genetics | 2 | 66.0 |
Ploidies | 9 | 3.0 |
*Liver Regeneration | 4 | 11.0 |
Down Syndrome/*metabolism | 3 | 14.0 |
*Chromosome Aberrations | 4 | 0.0 |
*Chromosome Disorders | 2 | 2.0 |
Chromosomes, Human, Pair 14 | 2 | 1.0 |
Chromosomes, Human, Pair 7 | 2 | 1.0 |
Vincristine/administration & dosage | 10 | 6.0 |
Renal Dialysis | 2 | 0.0 |
*Genetic Screening | 2 | 1.0 |
Carcinoma, Hepatocellular/mortality/*surgery | 3 | 75.0 |
Liver Neoplasms/mortality/*surgery | 3 | 60.0 |
Radiotherapy Dosage | 5 | 3.0 |
Teratoma/*blood/diagnosis/therapy | 2 | 100.0 |
*Portal Vein | 2 | 14.0 |
Diabetes Mellitus, Type 1/*blood | 4 | 2.0 |
Pregnancy in Diabetics/*blood | 7 | 20.0 |
Pregnancy, Multiple/*blood | 2 | 40.0 |
Antigens, CD15/analysis | 2 | 7.0 |
Tumor Markers, Biological/*analysis/blood | 2 | 10.0 |
Alkaline Phosphatase/*blood | 2 | 5.0 |
Chorionic Gonadotropin/metabolism | 3 | 9.0 |
*Enzyme Tests | 3 | 4.0 |
L-Lactate Dehydrogenase/metabolism | 2 | 1.0 |
Liver Diseases/*blood | 7 | 21.0 |
Liver Neoplasms/blood | 13 | 76.0 |
Electrophoresis/methods | 5 | 5.0 |
*Lectins | 2 | 1.0 |
Liver Diseases/blood/diagnosis | 2 | 66.0 |
*Apoptosis | 2 | 0.0 |
DNA-Binding Proteins/metabolism | 3 | 0.0 |
Rats, Inbred F344 | 2 | 0.0 |
Transcription Factors/*metabolism | 3 | 0.0 |
Liver Neoplasms/*pathology/surgery | 3 | 60.0 |
Epidermal Growth Factor/pharmacology | 2 | 0.0 |
*Gene Expression | 2 | 0.0 |
Lymph Node Excision | 4 | 5.0 |
Liver Diseases/blood/*diagnosis | 3 | 60.0 |
*Maternal-Fetal Exchange | 6 | 16.0 |
Perfusion | 2 | 0.0 |
Hepatitis, Viral, Human/blood | 4 | 57.0 |
Chi-Square Distribution | 2 | 0.0 |
Hepatitis/diagnosis | 3 | 60.0 |
*Antibodies, Monoclonal | 8 | 3.0 |
Fetal Membranes, Premature Rupture/*diagnosis | 2 | 100.0 |
Hepatitis C Antibodies/*blood | 2 | 22.0 |
Body Fluids/*metabolism | 2 | 9.0 |
DNA, Complementary | 3 | 0.0 |
Hominidae/*genetics | 2 | 1.0 |
Zinc Fingers | 2 | 0.0 |
Carcinoembryonic Antigen/*analysis | 25 | 46.0 |
Dogs | 4 | 0.0 |
Fetal Blood/metabolism | 2 | 3.0 |
CHO Cells | 2 | 0.0 |
Hamsters | 4 | 0.0 |
Immunochemistry | 4 | 1.0 |
Picibanil/*administration & dosage | 2 | 14.0 |
Enhancer Elements (Genetics)/*genetics | 2 | 2.0 |
Mice, Inbred Strains | 2 | 0.0 |
Algorithms | 4 | 1.0 |
DNA/biosynthesis | 3 | 0.0 |
Rabbits | 10 | 0.0 |
Liver/embryology/metabolism | 2 | 6.0 |
Sequence Deletion | 3 | 0.0 |
Patient Selection | 3 | 1.0 |
Carcinoma, Hepatocellular/*genetics/mortality/pathology | 2 | 66.0 |
Liver Neoplasms/*genetics/mortality/pathology | 2 | 66.0 |
Antigens, Neoplasm/*analysis | 11 | 2.0 |
Colonic Neoplasms/*diagnosis/surgery | 2 | 100.0 |
Neoplasm Recurrence, Local/diagnosis | 3 | 9.0 |
Peptides/*analysis | 3 | 4.0 |
Rectal Neoplasms/*diagnosis/surgery | 2 | 100.0 |
Drug Synergism | 2 | 0.0 |
Acetylcholinesterase/*analysis | 12 | 21.0 |
*Amniocentesis | 8 | 34.0 |
Schistosomiasis/*blood/complications | 2 | 100.0 |
Adenocarcinoma/metabolism/*pathology | 3 | 5.0 |
Histocytochemistry | 24 | 3.0 |
Drug Compounding | 2 | 13.0 |
Injections, Intra-Arterial | 8 | 21.0 |
Carcinoma, Hepatocellular/*drug therapy/*secondary | 2 | 100.0 |
Ovarian Neoplasms/*diagnosis | 3 | 25.0 |
Precancerous Conditions/*pathology | 2 | 7.0 |
*alpha-Fetoproteins | 5 | 83.0 |
*Chromosome Mapping | 2 | 0.0 |
*Chromosomes, Human, Pair 4 | 2 | 0.0 |
Linkage (Genetics) | 2 | 0.0 |
Nucleic Acid Hybridization | 4 | 0.0 |
Stomach Neoplasms/pathology | 2 | 8.0 |
Concanavalin A/*metabolism | 3 | 100.0 |
Placental Lactogen/analysis | 2 | 15.0 |
Dactinomycin/administration & dosage | 10 | 52.0 |
Liver Neoplasms/complications/*pathology | 2 | 100.0 |
Neoplasms/*blood | 5 | 11.0 |
Bilirubin/blood | 4 | 4.0 |
Liver/drug effects | 2 | 5.0 |
Carcinoma, Hepatocellular/mortality/pathology/*therapy | 3 | 100.0 |
Catheterization | 3 | 13.0 |
Liver Neoplasms/mortality/pathology/*therapy | 3 | 100.0 |
Mothers | 2 | 2.0 |
Thyrotropin/blood | 2 | 0.0 |
Promoter Regions (Genetics)/*genetics | 3 | 0.0 |
Recombinant Fusion Proteins/biosynthesis | 2 | 0.0 |
Chorionic Gonadotropin, beta Subunit, Human | 15 | 34.0 |
*Chorionic Villi Sampling | 2 | 8.0 |
Peptide Fragments/*blood | 6 | 7.0 |
Pregnancy Trimester, First/blood | 2 | 25.0 |
Carcinoma, Hepatocellular/*genetics | 5 | 5.0 |
DNA/metabolism | 2 | 0.0 |
Fibrosis | 2 | 1.0 |
Liver Cirrhosis/*genetics | 2 | 16.0 |
Liver Neoplasms/*genetics | 5 | 4.0 |
Down Syndrome/*blood/diagnosis | 2 | 100.0 |
Peptide Fragments/blood | 2 | 1.0 |
Electrophoresis, Agar Gel/*methods | 2 | 12.0 |
Chorionic Villi Sampling | 3 | 6.0 |
*Birth Weight | 2 | 5.0 |
Linear Models | 2 | 0.0 |
CCAAT-Enhancer-Binding Proteins | 2 | 1.0 |
DNA/genetics | 4 | 0.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
Isoelectric Focusing | 2 | 0.0 |
Drug Therapy, Combination | 8 | 0.0 |
China | 3 | 0.0 |
Pregnancy Trimester, Second/blood | 4 | 50.0 |
Biopsy, Needle/*methods | 2 | 16.0 |
Lung Neoplasms/pathology/secondary | 2 | 15.0 |
*Quality Assurance, Health Care | 2 | 9.0 |
Liver Cirrhosis/blood/complications | 3 | 30.0 |
Rectal Neoplasms/*metabolism/pathology | 3 | 60.0 |
Antigens, Tumor-Associated, Carbohydrate/*blood | 3 | 16.0 |
*Nuclear Proteins | 2 | 0.0 |
*Promoter Regions (Genetics) | 4 | 0.0 |
Protein Biosynthesis | 3 | 0.0 |
Liver Neoplasms/*drug therapy/surgery | 3 | 100.0 |
Liver Neoplasms/*blood/diagnosis/secondary | 2 | 100.0 |
Peptide Fragments/*analysis | 4 | 8.0 |
Testicular Neoplasms/*diagnosis/therapy | 2 | 100.0 |
Discriminant Analysis | 3 | 3.0 |
Pregnancy-Specific beta 1-Glycoproteins/*analysis | 4 | 3.0 |
Teratoma/diagnosis | 3 | 60.0 |
Abnormalities/diagnosis | 3 | 60.0 |
Tyrosine/blood | 2 | 11.0 |
Suspensions | 2 | 10.0 |
Diploidy | 2 | 1.0 |
Stomach Neoplasms/*metabolism/pathology | 4 | 7.0 |
Embolization, Therapeutic/*methods | 2 | 66.0 |
Thoracotomy | 2 | 28.0 |
Chromosome Aberrations/*diagnosis | 9 | 64.0 |
Pregnancy Proteins/*blood | 3 | 4.0 |
Picibanil/*therapeutic use | 2 | 13.0 |
Prenatal Care | 3 | 13.0 |
Blood Donors | 3 | 1.0 |
Abnormalities/*diagnosis | 6 | 75.0 |
Pregnancy/blood | 4 | 30.0 |
Progesterone/*blood | 2 | 5.0 |
DNA | 3 | 0.0 |
*Enhancer Elements (Genetics) | 4 | 1.0 |
Dysgerminoma/*pathology | 2 | 100.0 |
Amniotic Fluid/*metabolism | 7 | 17.0 |
Hepatitis B/*blood | 4 | 44.0 |
*Twins | 2 | 7.0 |
alpha-Fetoproteins/*chemistry/isolation & purification | 2 | 100.0 |
Green Fluorescent Proteins | 2 | 0.0 |
Luminescent Proteins/genetics | 2 | 1.0 |
Radioimmunoassay/*instrumentation | 2 | 66.0 |
Testicular Neoplasms/blood | 5 | 71.0 |
*Polymorphism, Genetic | 2 | 0.0 |
Clinical Trials | 3 | 0.0 |
Neuraminidase | 2 | 5.0 |
Stomach Neoplasms/blood | 2 | 40.0 |
Abdominal Muscles/*abnormalities | 4 | 57.0 |
Fallopian Tubes/*metabolism | 2 | 28.0 |
Neoplasm Recurrence, Local/pathology | 2 | 3.0 |
Mesonephroma/*drug therapy/pathology/surgery | 2 | 100.0 |
Methotrexate/administration & dosage | 3 | 3.0 |
Ferritin/*blood | 6 | 9.0 |
Down Syndrome/blood/*diagnosis/ultrasonography | 2 | 100.0 |
Pregnancy Complications/blood | 3 | 33.0 |
DNA, Neoplasm/*analysis | 6 | 3.0 |
Liver Neoplasms/metabolism/*pathology | 2 | 11.0 |
Hepatitis B Core Antigens/analysis | 3 | 33.0 |
Antibodies, Monoclonal/*diagnostic use/immunology | 2 | 8.0 |
Tumor Markers, Biological/*immunology | 2 | 8.0 |
Hypertension/*blood | 2 | 3.0 |
Pregnancy Complications, Cardiovascular/*blood | 2 | 9.0 |
Cholesterol/blood | 3 | 0.0 |
*Immunoenzyme Techniques | 6 | 4.0 |
Random Allocation | 3 | 0.0 |
Chromatography, Gel | 6 | 0.0 |
Sequence Homology, Nucleic Acid | 5 | 0.0 |
Doxorubicin/*therapeutic use | 2 | 8.0 |
Liposomes | 2 | 0.0 |
Teratoma/blood | 12 | 70.0 |
Chromosome Aberrations/*diagnosis/genetics | 2 | 40.0 |
Chromosomes, Human, Pair 21 | 2 | 1.0 |
DNA Probes | 3 | 0.0 |
China/epidemiology | 2 | 1.0 |
alpha-Fetoproteins/biosynthesis/*immunology | 3 | 100.0 |
Hydatidiform Mole/blood/*diagnosis | 2 | 100.0 |
Kinetics | 8 | 0.0 |
Papio | 2 | 1.0 |
Liver Diseases/etiology | 2 | 16.0 |
Liver Neoplasms/*surgery | 2 | 40.0 |
Neoplasms, Germ Cell and Embryonal/*blood | 2 | 100.0 |
Ovarian Neoplasms/*blood | 2 | 15.0 |
Fibronectins/analysis | 2 | 3.0 |
Immunoglobulin G/analysis | 6 | 1.0 |
Immunoglobulin M/analysis | 6 | 2.0 |
Infusions, Intra-Arterial/methods | 4 | 80.0 |
alpha-Fetoproteins/*secretion | 8 | 80.0 |
Placenta/physiology | 2 | 5.0 |
Methylation | 2 | 0.0 |
Amniocentesis/methods | 2 | 100.0 |
Pregnancy Complications/*diagnosis | 6 | 54.0 |
Chromosome Deletion | 2 | 0.0 |
Carcinoma, Hepatocellular/immunology | 2 | 50.0 |
Hybridomas | 3 | 2.0 |
Liver Neoplasms/immunology | 3 | 33.0 |
Estrogens/metabolism | 4 | 5.0 |
Prolactin/metabolism | 2 | 3.0 |
*Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
Heterozygote | 4 | 0.0 |
Fetal Diseases/*blood | 3 | 75.0 |
Kidney/*abnormalities | 2 | 8.0 |
Iodized Oil/administration & dosage/*therapeutic use | 2 | 66.0 |
Estrogens/*metabolism | 3 | 5.0 |
Rats, Inbred Strains | 7 | 0.0 |
*Radioimmunoassay | 2 | 5.0 |
Microscopy, Electron | 12 | 0.0 |
Antibodies, Monoclonal/*analysis | 2 | 4.0 |
Ovarian Neoplasms/metabolism/*pathology | 2 | 12.0 |
Pregnancy-Specific beta 1-Glycoproteins/biosynthesis | 2 | 50.0 |
Teratoma/metabolism/*pathology | 2 | 50.0 |
*Tumor Cells, Cultured | 2 | 2.0 |
Lung Neoplasms/*blood | 2 | 9.0 |
Genes, Structural | 3 | 0.0 |
Down Syndrome | 2 | 33.0 |
alpha-Fetoproteins/chemistry | 2 | 66.0 |
Immunoglobulins/analysis | 2 | 0.0 |
Blood | 2 | 1.0 |
Culture Media | 4 | 0.0 |
Granulosa Cells/*cytology | 2 | 40.0 |
Growth Substances/*pharmacology | 2 | 0.0 |
Platelet-Derived Growth Factor/pharmacology | 2 | 1.0 |
Transferrin/pharmacology | 2 | 7.0 |
Liver Cirrhosis/blood/*complications | 4 | 50.0 |
Indicators and Reagents | 2 | 0.0 |
alpha-Fetoproteins/*physiology | 2 | 100.0 |
Immunodiffusion | 20 | 7.0 |
Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Hemoglobins/analysis | 2 | 0.0 |
Embryonic and Fetal Development | 2 | 0.0 |
Liver Diseases/metabolism | 3 | 17.0 |
*Receptors, Peptide | 2 | 8.0 |
Bladder Neoplasms/blood | 2 | 50.0 |
Breast Neoplasms/blood | 2 | 9.0 |
Neoplasms/blood/*diagnosis | 2 | 50.0 |
Ovarian Neoplasms/blood | 4 | 30.0 |
alpha-Fetoproteins/immunology/*isolation & purification | 2 | 100.0 |
*Renal Dialysis | 2 | 0.0 |
Sepharose | 2 | 3.0 |
alpha-Fetoproteins/*isolation & purification/metabolism | 2 | 100.0 |
Liver/*radionuclide imaging | 2 | 33.0 |
*Hepatectomy | 5 | 13.0 |
Amniocentesis/*methods | 2 | 100.0 |
Liver Neoplasms, Experimental | 2 | 4.0 |
Carcinoma, Hepatocellular/*complications | 2 | 33.0 |
Liver Neoplasms/*complications | 2 | 28.0 |
CA-15-3 Antigen | 2 | 2.0 |
Abortion, Therapeutic/*methods | 2 | 100.0 |
Infant Mortality | 2 | 13.0 |
Infant, Low Birth Weight | 4 | 15.0 |
Antibodies, Monoclonal/immunology | 3 | 0.0 |
Immunotoxins/*pharmacology | 2 | 4.0 |
Cell Fusion | 3 | 1.0 |
DNA, Recombinant | 2 | 1.0 |
Intraoperative Period | 2 | 3.0 |
Liver Cirrhosis/pathology | 3 | 20.0 |
Neoplasms, Germ Cell and Embryonal/*drug therapy | 3 | 75.0 |
*Orchiectomy | 3 | 16.0 |
Retroperitoneal Space | 2 | 28.0 |
Testicular Neoplasms/blood/*pathology/surgery | 2 | 100.0 |
Neoplasms, Germ Cell and Embryonal/*blood/drug therapy | 2 | 100.0 |
Precipitin Tests | 2 | 0.0 |
Abnormalities, Multiple/*diagnosis | 4 | 50.0 |
Amniotic Fluid/analysis | 31 | 68.0 |
Placenta/analysis | 2 | 9.0 |
Isoenzymes | 2 | 1.0 |
Fetal Blood/analysis | 12 | 23.0 |
alpha-Fetoproteins/*analysis/diagnostic use | 3 | 100.0 |
Carcinoembryonic Antigen/*analysis/immunology | 2 | 100.0 |
Cytoplasm/ultrastructure | 2 | 3.0 |
Zinc/analysis | 2 | 22.0 |
Ferritin/analysis | 2 | 11.0 |
Isoenzymes/blood | 2 | 3.0 |
Estradiol/*analogs & derivatives/blood/metabolism | 2 | 100.0 |
Down Syndrome/*diagnosis/epidemiology | 2 | 100.0 |
Neoplasms/blood | 3 | 8.0 |
Neural Tube Defects/blood | 2 | 66.0 |
Amino Acids/analysis | 5 | 1.0 |
Carcinoma, Hepatocellular/genetics | 2 | 7.0 |
Plasmids/genetics | 2 | 0.0 |
Staining and Labeling/methods | 2 | 1.0 |
Periodic Acid-Schiff Reaction | 2 | 7.0 |
Mitomycin | 6 | 12.0 |
Mitomycins/administration & dosage | 4 | 22.0 |
Antigens, Surface/analysis | 2 | 0.0 |
Amniotic Fluid/*enzymology | 10 | 43.0 |
Spina Bifida Occulta/diagnosis | 5 | 83.0 |
Isomerism | 2 | 0.0 |
DNA/*genetics | 2 | 0.0 |
*Genes, Structural | 3 | 0.0 |
Luminescent Measurements | 2 | 2.0 |
alpha 1-Antitrypsin/*analysis | 2 | 8.0 |
Cell Nucleus/*analysis | 2 | 33.0 |
Aspartate Aminotransferases/analysis | 2 | 33.0 |
Liver/physiology | 2 | 3.0 |
*Body Weight | 3 | 4.0 |
Hepatitis B Antibodies/analysis | 5 | 27.0 |
*Enzyme-Linked Immunosorbent Assay | 5 | 6.0 |
Carcinoma, Hepatocellular/*analysis | 5 | 83.0 |
Liver Neoplasms/*analysis | 4 | 80.0 |
Carcinoma, Hepatocellular/*drug therapy/surgery | 2 | 100.0 |
Injections/methods | 2 | 25.0 |
Postoperative Care | 2 | 2.0 |
Daunorubicin/administration & dosage | 2 | 5.0 |
Amniotic Fluid/*analysis | 33 | 47.0 |
gamma-Glutamyltransferase/*analysis | 2 | 100.0 |
Ovarian Neoplasms/*drug therapy/surgery | 2 | 66.0 |
Epitopes/analysis | 2 | 0.0 |
Immunoassay/methods | 4 | 7.0 |
Teratoma/blood/*pathology/therapy | 2 | 100.0 |
Carcinoma, Hepatocellular/*immunology | 2 | 9.0 |
Hepatitis B/*immunology | 2 | 6.0 |
Hepatitis B Surface Antigens/*analysis | 10 | 34.0 |
Liver Neoplasms/*immunology | 2 | 10.0 |
*Lymphocyte Activation | 2 | 0.0 |
Doxorubicin/*administration & dosage/therapeutic use | 2 | 50.0 |
Carcinoma, Hepatocellular/analysis/*diagnosis | 2 | 100.0 |
Fucose/*analysis | 2 | 66.0 |
Liver Diseases/diagnosis | 4 | 50.0 |
Liver Neoplasms/analysis/*diagnosis | 2 | 100.0 |
Sacrococcygeal Region | 4 | 57.0 |
Neoplasm Proteins/*blood | 2 | 3.0 |
Diagnostic Errors | 3 | 4.0 |
Stomach Neoplasms/*pathology | 2 | 4.0 |
Carcinoma, Hepatocellular/drug therapy/*therapy | 2 | 100.0 |
Cisplatin/administration & dosage/*therapeutic use | 2 | 25.0 |
Liver Neoplasms/drug therapy/*therapy | 2 | 100.0 |
RNA, Messenger/*genetics | 3 | 0.0 |
Socioeconomic Factors | 2 | 1.0 |
Cyclins/genetics | 2 | 1.0 |
Teratoma/blood/drug therapy | 2 | 100.0 |
Testicular Neoplasms/blood/*drug therapy | 3 | 75.0 |
Encephalocele/*diagnosis | 2 | 66.0 |
Abortion, Threatened/blood | 2 | 33.0 |
*Genetic Counseling | 2 | 4.0 |
*Tumor Markers, Biological/analysis | 2 | 18.0 |
Concanavalin A/metabolism | 6 | 22.0 |
Mesonephroma/metabolism | 2 | 100.0 |
Ovarian Neoplasms/metabolism | 2 | 5.0 |
Yolk Sac/*metabolism | 2 | 66.0 |
Arachidonic Acids/metabolism | 2 | 5.0 |
Antigen-Antibody Reactions | 3 | 0.0 |
Epitopes/*analysis | 5 | 3.0 |
Hepatitis B Surface Antigens/immunology | 2 | 8.0 |
Mathematics | 3 | 1.0 |
alpha-Fetoproteins/*blood | 10 | 90.0 |
Leydig Cell Tumor/*metabolism/pathology | 2 | 33.0 |
Sertoli Cell Tumor/*metabolism/pathology | 2 | 66.0 |
alpha-Fetoproteins/*analysis/blood | 5 | 83.0 |
Mesonephroma/*drug therapy/mortality/surgery | 2 | 100.0 |
Ovarian Neoplasms/*drug therapy/mortality/surgery | 2 | 100.0 |
alpha-Fetoproteins/secretion | 2 | 66.0 |
Peptide Fragments/analysis | 3 | 1.0 |
Placenta/enzymology | 2 | 2.0 |
Vimentin/analysis | 2 | 0.0 |
Hepatitis B Core Antigens/*analysis | 2 | 66.0 |
Antineoplastic Combined Chemotherapy Protocols | 2 | 6.0 |
*Insulin-Like Growth Factor Binding Proteins | 2 | 16.0 |
Acetylcholinesterase/analysis | 5 | 14.0 |
Phosphopyruvate Hydratase/*analysis | 2 | 10.0 |
Carcinoma, Hepatocellular/diagnosis/*pathology | 2 | 66.0 |
Liver Neoplasms/diagnosis/*pathology | 2 | 50.0 |
*Ultrasonography | 9 | 29.0 |
alpha-Fetoproteins/blood/*metabolism | 2 | 100.0 |
Antibodies, Monoclonal/diagnostic use | 3 | 0.0 |
*alpha-Fetoproteins/analysis | 9 | 100.0 |
Liver Neoplasms/*prevention & control | 2 | 66.0 |
Albumins/biosynthesis | 2 | 16.0 |
Tumor Cells, Cultured/*metabolism | 2 | 6.0 |
Immunoassay/*methods | 3 | 3.0 |
*Pregnancy | 10 | 7.0 |
Iodine Radioisotopes/*diagnostic use | 3 | 5.0 |
Dysgerminoma/*blood/therapy | 3 | 100.0 |
Smoking | 3 | 0.0 |
Pregnancy Proteins/*metabolism | 2 | 3.0 |
Pregnancy Proteins/*analysis | 3 | 2.0 |
Abortion, Spontaneous/etiology | 2 | 33.0 |
*Chorionic Villi | 2 | 50.0 |
Ovarian Neoplasms/*pathology | 3 | 5.0 |
Breast Neoplasms/*metabolism | 2 | 0.0 |
Amniotic Fluid/analysis/*cytology | 2 | 100.0 |
Ovary/pathology | 3 | 10.0 |
Teratoma/*pathology | 2 | 66.0 |
Amniotic Fluid/*analysis/enzymology | 2 | 66.0 |
Fetal Death | 3 | 8.0 |
*Immunoelectrophoresis | 2 | 16.0 |
Immunoglobulin G/immunology | 2 | 0.0 |
Mesonephroma/*metabolism/pathology | 2 | 100.0 |
Teratoma/*metabolism/pathology | 3 | 75.0 |
Liver Neoplasms/pathology/secondary | 2 | 20.0 |
Fatty Acids/*metabolism | 2 | 2.0 |
Binding Sites, Antibody | 4 | 1.0 |
Horseradish Peroxidase/immunology | 2 | 40.0 |
Mitomycins/*administration & dosage | 2 | 50.0 |
Testicular Neoplasms/blood/*pathology | 2 | 100.0 |
Immunoglobulin A/analysis | 3 | 1.0 |
Pregnancy-Specific beta 1-Glycoproteins/*blood | 2 | 8.0 |
Fetal Blood/*analysis | 8 | 22.0 |
alpha-Fetoproteins/*isolation & purification | 7 | 100.0 |
Mesonephroma/analysis | 5 | 83.0 |
Immunoglobulins/*analysis | 2 | 2.0 |
Immune Sera | 4 | 1.0 |
Chlorambucil/administration & dosage | 4 | 57.0 |
Stomach Neoplasms/pathology/*secretion | 2 | 100.0 |
Neural Tube Defects/*diagnosis/metabolism | 3 | 100.0 |
Hepatitis B Antigens/analysis | 4 | 40.0 |
Testicular Neoplasms/*drug therapy | 2 | 28.0 |
Electrophoresis, Disc | 2 | 8.0 |
Fetal Death/diagnosis | 5 | 62.0 |
*Folic Acid/*analogs & derivatives | 2 | 100.0 |
Alkaline Phosphatase/blood | 6 | 4.0 |
Leydig Cell Tumor/diagnosis | 2 | 100.0 |
Carrier State/immunology | 2 | 13.0 |
Ovarian Neoplasms/*pathology/secretion | 2 | 100.0 |
*Blood Stains | 2 | 5.0 |
DNA Restriction Enzymes | 3 | 0.0 |
Neck/embryology/ultrasonography | 2 | 66.0 |
gamma-Glutamyltransferase/blood | 5 | 10.0 |
Hepatitis/metabolism | 2 | 33.0 |
Teratoma/metabolism | 2 | 40.0 |
Methotrexate/therapeutic use | 3 | 4.0 |
Castration | 7 | 15.0 |
Blood Proteins/*analysis | 2 | 1.0 |
Abnormalities, Multiple/diagnosis | 3 | 50.0 |
Anencephaly/diagnosis | 9 | 81.0 |
Meningomyelocele/diagnosis | 3 | 100.0 |
*Asialoglycoproteins | 2 | 25.0 |
Carcinoma, Hepatocellular/analysis | 6 | 100.0 |
Liver Neoplasms/analysis | 4 | 100.0 |
Neoplasms/*analysis | 3 | 33.0 |
Phytohemagglutinins/*metabolism | 2 | 50.0 |
Stomach Neoplasms/analysis | 2 | 100.0 |
Testicular Neoplasms/*analysis | 3 | 50.0 |
*Infant, Premature | 2 | 3.0 |
Antibodies, Neoplasm/*administration & dosage | 2 | 66.0 |
Hepatic Encephalopathy/blood | 2 | 40.0 |
Cyanogen Bromide | 2 | 3.0 |
Trypsin | 2 | 1.0 |
Liver Diseases/enzymology | 2 | 25.0 |
*Immunization, Passive | 2 | 3.0 |
gamma-Glutamyltransferase/*blood | 4 | 36.0 |
Antibodies/*immunology | 3 | 2.0 |
Hybridomas/immunology | 3 | 2.0 |
Sheep | 3 | 0.0 |
Double-Blind Method | 2 | 0.0 |
Chorionic Gonadotropin/*blood/metabolism | 2 | 100.0 |
Dysgerminoma/*metabolism/pathology | 3 | 75.0 |
Carbohydrates/analysis | 4 | 6.0 |
Chemistry | 3 | 1.0 |
Liver Neoplasms/chemically induced | 2 | 33.0 |
Drug Resistance | 2 | 0.0 |
Dysgerminoma/immunology | 2 | 100.0 |
Teratoma/immunology | 3 | 60.0 |
Ascitic Fluid/immunology | 2 | 9.0 |
Chorionic Gonadotropin/*analysis/blood | 4 | 100.0 |
Dactinomycin/therapeutic use | 2 | 50.0 |
alpha-Fetoproteins/cerebrospinal fluid/*metabolism | 2 | 100.0 |
Meningomyelocele/*diagnosis | 2 | 100.0 |
Cytosol/*analysis | 2 | 66.0 |
Dysgerminoma/blood | 6 | 66.0 |
Neoplasms, Experimental/drug therapy | 2 | 8.0 |
Choriocarcinoma/analysis | 3 | 60.0 |
Dysgerminoma/analysis | 3 | 100.0 |
Teratoma/analysis | 4 | 80.0 |
*Antineoplastic Combined Chemotherapy Protocols | 3 | 21.0 |
Bleomycin/therapeutic use | 4 | 40.0 |
Cyclophosphamide/therapeutic use | 3 | 3.0 |
Vincristine/therapeutic use | 2 | 5.0 |
alpha-Fetoproteins/blood | 2 | 66.0 |
Pre-Eclampsia/blood | 2 | 11.0 |
Mesonephroma/*blood | 2 | 100.0 |
Glucose/*analysis | 2 | 33.0 |
Hepatitis B e Antigens/analysis | 2 | 13.0 |
Vinblastine/therapeutic use | 3 | 42.0 |
*Infant, Newborn | 3 | 6.0 |
*Evolution | 2 | 1.0 |
alpha-Fetoproteins/*immunology/isolation & purification | 2 | 100.0 |
Antibodies, Viral/*analysis | 2 | 3.0 |
Hepatitis B Antibodies/*analysis | 2 | 15.0 |
*Pregnancy, Multiple | 4 | 30.0 |
Hyalin/*analysis | 2 | 100.0 |
*Infant, Low Birth Weight | 3 | 13.0 |
*Immunosuppression | 2 | 2.0 |
Lymphocyte Culture Test, Mixed | 3 | 0.0 |
Cystic Fibrosis/*blood | 2 | 40.0 |
Ascitic Fluid/analysis | 3 | 42.0 |
Abortion, Spontaneous | 3 | 11.0 |
Genetic Screening/methods | 2 | 1.0 |
Choriocarcinoma/blood | 6 | 46.0 |
Anencephaly/*diagnosis | 6 | 100.0 |
Placental Lactogen/blood | 3 | 12.0 |
*Antibody Formation | 3 | 3.0 |
Cervix Neoplasms/blood | 2 | 22.0 |
Uterine Neoplasms/*blood | 2 | 9.0 |
Fetal Distress/diagnosis | 3 | 100.0 |
Sheep/immunology | 2 | 8.0 |
Placental Lactogen/*blood | 4 | 12.0 |
Concanavalin A/*diagnostic use | 2 | 100.0 |
Estradiol/blood | 2 | 0.0 |
Hormones/*blood | 2 | 1.0 |
Pregnancy Tests | 2 | 20.0 |
Laparotomy | 2 | 11.0 |
Mediastinal Neoplasms/blood | 2 | 100.0 |
Retroperitoneal Neoplasms/blood | 2 | 100.0 |
Rabbits/immunology | 2 | 2.0 |
Jaundice, Neonatal/*blood | 6 | 75.0 |
Ataxia Telangiectasia/blood | 2 | 100.0 |
Fetus/metabolism | 4 | 2.0 |
Cholinesterases/*analysis | 2 | 20.0 |
Carcinoma, Hepatocellular/diagnosis | 2 | 66.0 |
Ovarian Neoplasms/*blood/pathology | 2 | 40.0 |
Hemoperfusion/*methods | 2 | 33.0 |
Hepatic Encephalopathy/blood/*therapy | 2 | 66.0 |
Haplorhini | 4 | 1.0 |
Teratoma/*blood | 2 | 100.0 |
Immunosuppression | 2 | 1.0 |
Scotland | 2 | 5.0 |
Central Nervous System/*abnormalities | 3 | 50.0 |
Carcinoma, Hepatocellular/blood/*diagnosis/enzymology | 2 | 100.0 |
Liver Neoplasms/blood/*diagnosis/enzymology | 2 | 100.0 |
Methods | 2 | 0.0 |
Liver Cirrhosis/immunology | 2 | 14.0 |
Dysgerminoma/*blood | 2 | 66.0 |
*Antigen-Antibody Complex | 2 | 3.0 |
Alpha-Globulins | 3 | 75.0 |
*Antigens, Neoplasm/analysis | 2 | 66.0 |
Colonic Neoplasms/immunology | 2 | 9.0 |
Ovarian Neoplasms/*immunology | 2 | 6.0 |
Central Nervous System/abnormalities | 2 | 100.0 |
Macaca mulatta | 2 | 0.0 |
Neoplasms, Experimental/metabolism | 3 | 25.0 |
*alpha 1-Antitrypsin/analysis | 2 | 100.0 |
Ovarian Neoplasms/*blood/therapy | 2 | 100.0 |
Nervous System/embryology | 3 | 9.0 |
Spinal Dysraphism/*diagnosis | 5 | 100.0 |
Fibrin Fibrinogen Degradation Products/*analysis | 2 | 4.0 |
Teratoma/*blood/pathology | 2 | 100.0 |
Progesterone/blood | 2 | 0.0 |
Immunity, Cellular | 2 | 0.0 |
Spinal Dysraphism/diagnosis | 3 | 75.0 |
Fetal Proteins/*analysis | 19 | 90.0 |
Fetal Proteins/*metabolism | 6 | 42.0 |
New Guinea | 2 | 18.0 |
*Fetal Proteins/analysis | 2 | 100.0 |
Antibodies/isolation & purification | 2 | 11.0 |
Fetal Proteins/*isolation & purification | 2 | 100.0 |
Liver/*enzymology | 2 | 0.0 |
